KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Other Working Capital Changes (2016 - 2025)

Neogenomics (NEO) has disclosed Other Working Capital Changes for 16 consecutive years, with -$326000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 102.93% year-over-year to -$326000.0, compared with a TTM value of -$323000.0 through Dec 2025, down 104.73%, and an annual FY2025 reading of -$323000.0, down 104.73% over the prior year.
  • Other Working Capital Changes was -$326000.0 for Q4 2025 at Neogenomics, down from $190000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $11.1 million in Q4 2024 and bottomed at -$9.3 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is -$877350.0, with a median of -$191500.0 recorded in 2024.
  • The sharpest move saw Other Working Capital Changes soared 3123.53% in 2021, then tumbled 2165.19% in 2023.
  • Year by year, Other Working Capital Changes stood at -$9.1 million in 2021, then skyrocketed by 83.83% to -$1.5 million in 2022, then fell by 19.1% to -$1.8 million in 2023, then surged by 734.59% to $11.1 million in 2024, then plummeted by 102.93% to -$326000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for NEO at -$326000.0 in Q4 2025, $190000.0 in Q3 2025, and $903000.0 in Q2 2025.